Lymphosarcoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: LYM019 MIFTS: 55	Lymphosarcoma Categories: Rare diseases, Cancer diseases, Immune diseases
Genes Tissues Related diseases Publications Pathways Drugs Download Expand all tables

Sources

Aliases & Classifications for Lymphosarcoma

MalaCards integrated aliases for Lymphosarcoma:

Name: Lymphosarcoma ¹² ⁷⁶ ⁵³ ⁵⁵ ¹⁵

Malignant Lymphoma ¹²

Lymphoma, Diffuse ⁷³

Diffuse Lymphoma ¹²

Lymphoma ⁷³

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Immune diseases

See all MalaCards categories (disease lists)

ICD10: ³³

Neoplasms

Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue

Other and unspecified types of non-Hodgkin lymphoma

Non-Hodgkin lymphoma, unspecified

External Ids:

Disease Ontology ¹² DOID:8675

ICD10 ³³ C85.9

ICD9CM ³⁵ 200.0 200.1 200.7

MeSH ⁴⁴ D008228

NCIt ⁵⁰ C26919 C27824 C3210 more

UMLS ⁷³ C0024302 C0024304 C0024305 more

Sources

Summaries for Lymphosarcoma

MalaCards based summary : Lymphosarcoma, also known as malignant lymphoma, is related to testicular lymphoma and reticulosarcoma. An important gene associated with Lymphosarcoma is MIR19A (MicroRNA 19a
six mature miRNAs (miR-17-5p, miR-17-3p, miR-19a, miR-19b, miR-20 and miR-92-1) in the cell lines with a 13q31 gain/amplification displays overexpression significantly higher than in those without.), and among its related pathways/superpathways are Chromatin Regulation / Acetylation and B cell receptor signaling pathway (KEGG). The drugs Teniposide and rituximab have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone, and related phenotype is Reduced mammosphere formation.

Wikipedia : ⁷⁶ Lymphoma is a group of blood cancers that develop from lymphocytes (a type of white blood cell). The... more...

Sources

Related Diseases for Lymphosarcoma

Diseases related to Lymphosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 113)

#	Related Disease	Score	Top Affiliating Genes
1	testicular lymphoma	32.0	BCL6 PTPRC
2	reticulosarcoma	29.5	BCL6 PTPRC
3	mediastinal malignant lymphoma	12.0
4	burkitt lymphoma	11.5
5	lymphoproliferative syndrome, x-linked, 1	11.4
6	mantle cell lymphoma	11.3
7	breast lymphoma	11.2
8	lymphoproliferative syndrome 2	11.0
9	diffuse large b-cell lymphoma	10.9
10	lymphoma, small cleaved-cell, diffuse	10.9
11	meningococcal infection	10.5	G6PD GSR
12	glucosephosphate dehydrogenase deficiency	10.5	G6PD H6PD
13	leukemia	10.4
14	testis seminoma	10.4	DNMT3A PTPRC
15	heart lymphoma	10.4	BCL6 PTPRC
16	nodular lymphocyte predominant hodgkin lymphoma	10.3	BCL6 PTPRC
17	senile cataract	10.3	G6PD GSR
18	epidural neoplasm	10.3	BCL6 PTPRC
19	plasmablastic lymphoma	10.2	BCL6 PTPRC
20	bone lymphoma	10.2	BCL6 CD22
21	lymphatic system cancer	10.2	BCL6 PTPRC
22	small intestine lymphoma	10.1	CD22 CTSL PTPRC
23	lymphoma	10.1
24	leukemia, acute lymphoblastic 3	10.1
25	lung lymphoma	10.0	BCL6 CD22
26	colon lymphoma	10.0	BCL6 CD22 PTPRC
27	hepatitis	9.9
28	mediastinitis	9.9
29	mature b-cell neoplasm	9.9	BCL6 PTPRC
30	acute leukemia	9.8
31	inflammatory bowel disease	9.8
32	hypersplenism	9.8
33	myeloid leukemia	9.8
34	neuropathy	9.8
35	lymphoid leukemia	9.7
36	thrombosis	9.7
37	sarcoma	9.7
38	hemopericardium	9.7
39	pericardial effusion	9.7
40	uveitis	9.7
41	plasmacytoma	9.7
42	histiocytoma	9.7
43	pneumonia	9.7
44	hodgkin's granuloma	9.7
45	paraneoplastic syndromes	9.7
46	lymphoma, hodgkin, classic	9.6	BCL6 MIR20A PTPRC
47	hematologic cancer	9.6	BCL6 CD22 NR3C1 PTPRC
48	complement component 4, partial deficiency of	9.6
49	holt-oram syndrome	9.6
50	ascites, chylous	9.6

Graphical network of the top 20 diseases related to Lymphosarcoma:

Sources

Symptoms & Phenotypes for Lymphosarcoma

GenomeRNAi Phenotypes related to Lymphosarcoma according to GeneCards Suite gene sharing:

²⁶

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Reduced mammosphere formation	GR00396-S	9.1	BCL6 CD22 CTSL DNMT3A NR3C1 PTPRC

Sources

Drugs & Therapeutics for Lymphosarcoma

Drugs for Lymphosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 962)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Teniposide

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

29767-20-2

34698

rituximab

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

174722-31-7

10201696

Gemcitabine

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

95058-81-4

60750

Vidarabine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

24356-66-9

32326 21704

Lenograstim

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

135968-09-1

Fludarabine

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

21679-14-1, 75607-67-9

30751

Etoposide

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

33419-42-0

36462

Menthol

Approved

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1

2216-51-5

16666

Cisplatin

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

15663-27-1

84093 441203 2767

Doxorubicin

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

23214-92-8

31703

Dasatinib

Approved, Investigational

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

302962-49-8

3062316

Hydrocortisone

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

50-23-7

5754

Dacarbazine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

4342-03-4

5351166

Denileukin diftitox

Approved, Investigational

Phase 4,Phase 2,Phase 1,Not Applicable

173146-27-5

Vinblastine

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

865-21-4

13342 241903

Mechlorethamine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

51-75-2

4033

Ifosfamide

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

3778-73-2

3690

Tropisetron

Approved, Investigational

Phase 4,Not Applicable

105826-92-4, 89565-68-4

5595

Iron

Approved

Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable

7439-89-6

23925

Aprepitant

Approved, Investigational

Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1

170729-80-3

151165 6918365

Dopamine

Approved

Phase 4,Phase 3,Phase 2,Not Applicable

51-61-6, 62-31-7

681

Clarithromycin

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

81103-11-9

84029

Mesna

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

3375-50-6

598

Vincristine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

2068-78-2, 57-22-7

5978

Methotrexate

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

1959-05-2, 59-05-2

126941

Cytarabine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

147-94-4

6253

Zidovudine

Approved

Phase 4,Phase 2,Not Applicable

30516-87-1

35370

Miconazole

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

22916-47-8

4189

Thiotepa

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

52-24-4

5453

Cyclophosphamide

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

50-18-0, 6055-19-2

2907

Metronidazole

Approved

Phase 4,Phase 3,Phase 2

443-48-1

4173

Dexamethasone

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

50-02-2

5743

Valproic Acid

Approved, Investigational

Phase 4,Phase 2,Phase 1,Early Phase 1

99-66-1

3121

Busulfan

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

55-98-1

2478

Idarubicin

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

58957-92-9

42890

Prednisolone

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

50-24-8

5755

Oxaliplatin

Approved, Investigational

Phase 4,Phase 2,Phase 3,Phase 1

61825-94-3

5310940 9887054 43805 6857599

Palonosetron

Approved, Investigational

Phase 4,Phase 2,Not Applicable

135729-61-2, 119904-90-4, 135729-56-5

148211

Everolimus

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

159351-69-6

6442177

Amoxicillin

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Not Applicable

26787-78-0

33613

Tacrolimus

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

104987-11-3

445643 439492

Melphalan

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

148-82-3

4053 460612

Mycophenolic acid

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

24280-93-1

446541

Mitoxantrone

Approved, Investigational

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

65271-80-9

4212

Bexarotene

Approved, Investigational

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

153559-49-0

82146

Daunorubicin

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

20830-81-3

30323

Benzocaine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

1994-09-7, 94-09-7

2337

Amifostine

Approved, Investigational

Phase 4,Phase 2,Phase 1

20537-88-6

2141

Mycophenolate mofetil

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

128794-94-5

5281078

Granisetron

Approved, Investigational

Phase 4,Phase 2,Not Applicable

109889-09-0

3510

Interventional clinical trials:

(show top 50) (show all 6499)

#	Name	Status	NCT ID	Phase	Drugs
1	Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults	Unknown status	NCT00797810	Phase 4	Rituximab
2	Low Grade Lymphoma	Unknown status	NCT01698866	Phase 4
3	CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL	Unknown status	NCT02533700	Phase 4	CEOP/IVE/GDP chemotherapy regimen;CEOP chemotherapy regimen for 6 cycles
4	Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PET	Unknown status	NCT00188149	Phase 4	Combined chemotherapy (ABVD, BACOPP-D)
5	Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH)	Unknown status	NCT02347878	Phase 4	Aprepitant
6	Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice	Unknown status	NCT01273441	Phase 4	PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
7	Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients	Unknown status	NCT02690922	Phase 4	Dasatinib;prednisone;dexamethasone;methotrexate
8	HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALL	Unknown status	NCT01873807	Phase 4	IDA;CTX;VP-16
9	Medical Research Council (MRC) Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003	Unknown status	NCT00222612	Phase 4	Standard childhood UK ALL protocol;Intensified treatment including Capizzi maintenance
10	Poly(Ethylene Glycol)(PEG)-Asparaginase During Two Treatment Courses	Unknown status	NCT00192673	Phase 4	PEG-asparaginase
11	German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)	Unknown status	NCT00198991	Phase 4	Cyclophosphamide;Dexamethasone;Vincristine;daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Prednisolone;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Cladribine
12	German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia	Unknown status	NCT00198978	Phase 4	Cyclophosphamide;Dexamethasone / Prednisolone;Cytarabine;Idarubicin;Granulocyte-Colony-Stimulating Factor;Mercaptopurine;Methotrexate;Rituximab;HDARAC;Vincristine;Depocyte;Asparaginase
13	Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia	Unknown status	NCT01990807	Phase 4	Idarubicin(IDA)
14	Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer	Unknown status	NCT00274885	Phase 4	oxaliplatin
15	Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin’s Lymphoma	Completed	NCT00168727	Phase 4	ibritumomab tiuxetan (Zevalin®)
16	An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma	Completed	NCT01833039	Phase 4	Ibrutinib
17	Treatment of Peripheral T-cell Lymphoma	Completed	NCT01664975	Phase 4	GDPT regimen;CHOP regimen
18	PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy	Completed	NCT02805218	Phase 4	PEG-rhG-CSF
19	MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.	Completed	NCT00430352	Phase 4	rituximab [MabThera/Rituxan]
20	Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)	Completed	NCT00211198	Phase 4	ONTAK (denileukin difitox, DAB389IL-2)
21	Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)	Completed	NCT01007448	Phase 4	bexarotene;bexarotene
22	Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma	Completed	NCT00969462	Phase 4	Doxorubicin
23	Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms	Completed	NCT01164475	Phase 4	Granulocyte-colony stimulating factor (G-CSF);Fixed Dose Plerixafor;Weight-Based Plerixafor
24	German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults	Completed	NCT00199017	Phase 4	Dexamethasone/Prednisolone;Cyclophosphamide;Vincristine;Daunorubicin;Asparaginase;G-CSF;Mercaptopurine;Cytarabine;Methotrexate;VP16;Vindesine;Adriamycin;Thioguanine;HDARAC;Cladribine
25	Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma	Completed	NCT01124526	Phase 4	Rituximab Fludarabine Cyclophosphamide
26	Whole Brain Irradiation in Primary Central Nervous System (CNS) Lymphoma (PCNSL)	Completed	NCT00153530	Phase 4	methotrexate
27	Prophylactic Use of Entecavir for Non-Hodgkin's Lymphoma Patients With Resolved Hepatitis B	Completed	NCT00926757	Phase 4	Entecavir prophylaxis;Therapeutic entecavir
28	Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene of Cutaneous T Cell Lymphoma	Completed	NCT01569724	Phase 4
29	An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL)	Completed	NCT02782845	Phase 4	Chemotherapy;Immunochemotherapy;Pegfilgrastim
30	LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV)	Completed	NCT00466258	Phase 4	R-CHOP;Highly active antiretroviral therapy;Central nervous system (CNS) prophylaxis;Prophylaxis of opportunistic infections and support treatment
31	Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients	Completed	NCT00050999	Phase 4	ONTAK
32	Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients	Completed	NCT00051012	Phase 4	ONTAK
33	Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma	Completed	NCT00090038	Phase 4	rituximab
34	Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy	Completed	NCT00230217	Phase 4	Rasburicase (SR29142)
35	Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults	Completed	NCT00199082	Phase 4	Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
36	Prevention of CHOP-induced Chronic Cardiotoxicity	Completed	NCT00162955	Phase 4	Valsartan
37	Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A	Completed	NCT00221039	Phase 4	Methoxsalen+ECP
38	Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab)	Completed	NCT01418430	Phase 4	CHOP-daclizumab
39	PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation	Completed	NCT00352703	Phase 4	Kepivance (Palifermin)
40	Epoetin Alfa (Hemax®) Phase IV Study in Chemotherapy Induced Anemia	Completed	NCT01374373	Phase 4
41	Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving Chemotherapy	Completed	NCT00524407	Phase 4	Epoetin alfa
42	Evaluation of the Analgesy With Emla and/or Nitrous Oxide in Pediatric Patients for Lumbar Puncture	Completed	NCT00808171	Phase 4	Livopan;Livopan;EMLA
43	ALL-REZ BFM 2002: Multi-Center Study for Children With Relapsed Acute Lymphoblastic Leukemia	Completed	NCT00114348	Phase 4
44	DepoCyt Therapy in Patients With Neoplastic Meningitis From Lymphoma or a Solid Tumor	Completed	NCT00029523	Phase 4	Intrathecal (injected into the spinal fluid) DepoCyt;Intrathecal methotrexate;Intrathecal cytarabine (also known as ara-C)
45	AMENO-2: Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors	Completed	NCT00415103	Phase 4	Aprepitant;Palonosetron;Granisetron
46	A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer	Completed	NCT00277160	Phase 4	Neulasta (pegfilgrastim)
47	10-day Versus 14-day Concomitant PAMC as First-line Treatment Strategy for the Eradication of H. Pylori Infection	Completed	NCT02959255	Phase 4	Esomeprazole
48	Subcutaneous Amifostine Safety Study	Completed	NCT00158041	Phase 4	Amifostine administered subcutaneously
49	Intraluminal Therapy for Helicobacter Pylori Infection	Completed	NCT03124420	Phase 4	Lansoprazole;Amoxicillin;Clarithromycin
50	Bone Marrow Transplantation in Treating Patients With Hematologic Cancer	Completed	NCT00003398	Phase 4	cyclophosphamide;thiotepa

Search NIH Clinical Center for Lymphosarcoma

Inferred drug relations via UMLS ⁷³ / NDF-RT ⁵¹ :

asparaginase

cytarabine

cytarabine liposome

irinotecan

irinotecan hydrochloride

mitoxantrone

mitoxantrone hydrochloride

thiotepa

Sources

Genetic Tests for Lymphosarcoma

Sources

Anatomical Context for Lymphosarcoma

MalaCards organs/tissues related to Lymphosarcoma:

⁴¹

B Cells, T Cells, Bone, Bone Marrow, Lung, Myeloid, Nk Cells

Sources

Publications for Lymphosarcoma

Articles related to Lymphosarcoma:

(show top 50) (show all 1246)

#	Title	Authors	Year
1	Secondary Syphilis with Tonsillar and Cervical Lymphadenopathy and a Pulmonary Lesion Mimicking Malignant Lymphoma. ( 29502129 )	Komeno Y....Ryu T.	2018
2	Myeloid Sarcoma Presented as Generalized Lymphadenopathy: Mimicking Malignant Lymphoma. ( 29398826 )	Gajendra S....Sachdev R.	2018
3	Cytomegalovirus retinitis in a patient with secondary acute lymphosarcoma leukemia undergoing allogeneic hematopoietic stem-cell transplantation: A rare case report: a care-compliant article. ( 28489788 )	Zhao N....Xu J.	2017
4	Association between increased serum GP88 (progranulin) concentrations and prognosis in patients with malignant lymphomas. ( 28823651 )	Yamamoto Y....Tsurumi H.	2017
5	miRNases: Novel peptide-oligonucleotide bioconjugates that silence miR-21 in lymphosarcoma cells. ( 28126663 )	Patutina O.A....Zenkova M.A.	2017
6	CD3 and CD20 Immunohistochemical Staining Patterns of Bone Marrow-Infiltrating Malignant Lymphoma Cells. ( 28442514 )	Lee E.J....Lee Y.K.	2017
7	Lymphedema of the Lower Extremities due to Refractory Malignant Lymphoma Treated by Lymphaticovenous Anastomosis. ( 28894674 )	Ishii N....Kishi K.	2017
8	Primary Malignant Lymphoma Originating from the Chest Wall without Preceding Pleural Disease. ( 28321070 )	Iwasa Y....Kimura H.	2017
9	Acute Lameness in a Roller Pigeon ( Columba livia ) with Multicentric Lymphosarcoma. ( 28665728 )	Williams S.M....Gogal R.M.	2017
10	Immunohistochemical analysis of the novel marginal zone B-cell marker IRTA1 in malignant lymphoma. ( 27666766 )	Ikeda J.I....Morii E.	2017
11	Association of BoLA-DRB3.2 Alleles with BLV Infection Profiles (Persistent Lymphocytosis/Lymphosarcoma) and Lymphocyte Subsets in Iranian Holstein Cattle. ( 26782666 )	Nikbakht Brujeni G....Esmailnejad A.	2016
12	[Malignant lymphoma presented as recurrent multiple cranial nerve palsy after spontaneous regression of oculomotor nerve palsy: A case report]. ( 26616489 )	Hirose T....Kimura F.	2016
13	Gene mutations in malignant lymphoma. ( 28090025 )	Chiba S.	2016
14	Management of Primary Malignant Lymphoma of the Parotid Gland in a series of 745 patients. ( 26871900 )	Lieder A....Franzen A.	2016
15	Aberrant expression of napsin A in a subset of malignant lymphomas. ( 26400099 )	Nam S.J....Jeon Y.K.	2016
16	Primary malignant lymphoma of the uterus: a report of four cases. ( 27172736 )	Terada T.	2016
17	Massive Localized Lymphedema in the Morbidly Obese Patient: A Clinical Entity Mimicking Lymphosarcoma. ( 26367787 )	Kotidis E....Kanellos I.	2015
18	Cardiac Sarcoidosis Masked by Malignant Lymphoma. ( 27094123 )	Tobita T....Hagiwara N.	2015
19	Pattern of MEF2B expression in lymphoid tissues and in malignant lymphomas. ( 26089142 )	KrenA!cs D....KrenA!cs L.	2015
20	Primary malignant lymphoma of the trigeminal nerve: case report and literature review. ( 25797078 )	Ogiwara T....Hongo K.	2015
21	Comparison of field-in-field radiotherapy with conformal radiotherapy for unilateral cervical malignant lymphoma. ( 26289909 )	Yamashita M....Kanazawa S.	2015
22	microRNA in Malignant Lymphoma. ( 26658995 )	Tagawa H.	2015
23	Genomic alterations underlying immune privilege in malignant lymphomas. ( 26049756 )	Mottok A....Steidl C.	2015
24	Primary malignant lymphoma combined with clinically &quot;silent&quot; pheochromocytoma in the same adrenal gland. ( 26419235 )	Babinska A....Sworczak K.	2015
25	Primary malignant lymphoma of the uterus and broad ligament: a case report and review of literature. ( 25674001 )	Chen R....Chen B.	2015
26	South African report of first case of chromoblastomycosis caused by Cladosporium (syn Cladophialophora) carrionii infection in a cat with feline immunodeficiency virus and lymphosarcoma. ( 25425600 )	Zambelli A.B....Griffiths C.A.	2015
27	Common consensus LNA probe for quantitative PCR assays in cancer: vehicles for minimal residual disease detection in t(11;14) and t(14;18) positive malignant lymphomas. ( 24631717 )	SA...Nyvold C.G.	2014
28	Refractory seborrheic dermatitis of the head in a patient with malignant lymphoma. ( 25566053 )	Okada K....Miyachi Y.	2014
29	Role of polymorphic loci in HLA-region rs2647012 and rs805288 in the development of non-Hodgkin's malignant lymphomas in Western Siberia. ( 24958370 )	Weiner A.S....Filipenko M.L.	2014
30	Monoclonal hyperglobulinemia in lymphosarcoma in a cockatiel (Nymphicus hollandicus) and a blue and gold macaw (Ara ararauna). ( 25055643 )	Lennox A....Cray C.	2014
31	Takayasu's arteritis misdiagnosed as mediastinal malignant lymphoma: a case report and review of the literature. ( 24977018 )	Hong C....Gu Y.	2014
32	Cloacolithiasis and intestinal lymphosarcoma in an African black-footed penguin (Spheniscus demersus). ( 25000718 )	Jones K.L....MacLean R.A.	2014
33	Focal thoracolumbar spinal cord lymphosarcoma in a ferret (Mustela putorius furo). ( 24982519 )	Ingrao J.C....Smith D.	2014
34	Analysis of the association of polymorphic loci rs917997 in IL18RAP gene and rs187238 in IL18 gene with the risk for non-Hodgkin's malignant lymphomas in Novosibirsk population. ( 24909718 )	Surovtseva M.N....Filipenko M.L.	2014
35	Hematopathology: LC14-1 SMALL B-CELL LYMPHOMAS. DIAGNOSIS OF MALIGNANT LYMPHOMAS IN 2014. ( 25188095 )	Quintanilla-Fend L.	2014
36	Percutaneous image-guided biopsy for non-mass-forming isolated splenomegaly and suspected malignant lymphoma. ( 25365519 )	Tokue H....Tsushima Y.	2014
37	Dynamics of oxidative modification of proteins and specific structural features of blood plasma from animals with Pliss lymphosarcoma. ( 23658922 )	Kulakova K.V....Makusheva M.A.	2013
38	c-Myc and E2F1 drive PBK/TOPK expression in high-grade malignant lymphomas. ( 23237560 )	Hu F....Rapoport A.P.	2013
39	Isolated primary malignant lymphoma arising from the optic chiasm. ( 23932421 )	Tsutsumi K....Hongo K.	2013
40	Malignant lymphoma in primary SjAPgren's syndrome: an update on the pathogenesis and treatment. ( 23816048 )	Routsias J.G....Voulgarelis M.	2013
41	ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). ( 23175624 )	Ghielmini M....Dreyling M.	2013
42	Expression of FoxO3a in clinical cases of malignant lymphoma. ( 24021689 )	Ikeda J....Morii E.	2013
43	Role of microRNA in the pathogenesis of malignant lymphoma. ( 23551855 )	Tagawa H....Sawada K.	2013
44	Reactivation of hepatitis B virus in patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma. ( 23926082 )	Matsui T....Tanaka Y.	2013
45	The effect of novel rhenium compounds on lymphosarcoma, PC-3 prostate and myeloid leukemia cancer cell lines and an investigation on the DNA binding properties of one of these compounds through electronic spectroscopy. ( 25221731 )	Parson C....Mandal S.K.	2013
46	Secondary syphilis presenting as a generalized lymphadenopathy: clinical mimicry of malignant lymphoma. ( 23680905 )	Park S.Y....Kim d.o. .Y.	2013
47	Feline small cell lymphosarcoma versus inflammatory bowel disease: diagnostic challenges. ( 23677821 )	Al-Ghazlat S....Ferreri J.	2013
48	Posterior mediastinal malignant lymphoma mimicking a neurogenic tumor. ( 23336918 )	Ohtaki Y....Takeyoshi I.	2013
49	Primary malignant lymphoma in the deep palmar tissue. ( 22496181 )	Takase K....Yamamoto K.	2013
50	Feline small cell lymphosarcoma versus inflammatory bowel disease: treatment and prognosis. ( 23814916 )	de Rezende C.E....Al-Ghazlat S.	2013

Sources

Genes for Lymphosarcoma

Genes related to Lymphosarcoma (0 elite genes):

(show all 13)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	MIR19A	MicroRNA 19a six mature miRNAs (miR-17-5p, miR-17-3p, miR-19a, miR-19b, miR-20 and miR-92-1) in the cell lines with a 13q31 gain/amplification displays overexpression significantly higher than in those without.	RNA Gene	50	Unspecified ⁴⁷	16167061
2	MIR20A	MicroRNA 20a six mature miRNAs (miR-17-5p, miR-17-3p, miR-19a, miR-19b, miR-20 and miR-92-1) in the cell lines with a 13q31 gain/amplification displays overexpression significantly higher than in those without.	RNA Gene	50	Unspecified ⁴⁷	16167061
3	MIR92A1	MicroRNA 92a-1 six mature miRNAs (miR-17-5p, miR-17-3p, miR-19a, miR-19b, miR-20 and miR-92-1) in the cell lines with a 13q31 gain/amplification displays overexpression significantly higher than in those without.	RNA Gene	50	Unspecified ⁴⁷	16167061
4	BCL6	B Cell CLL/Lymphoma 6	Protein Coding	22.9	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	9200999 16867873 8750627 (more) 8623923
5	NR3C1	Nuclear Receptor Subfamily 3 Group C Member 1	Protein Coding	21.48	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	PTPRC	Protein Tyrosine Phosphatase, Receptor Type C	Protein Coding	20.77	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	GSR	Glutathione-Disulfide Reductase	Protein Coding	16.65	GeneCards inferred via : Publications (show sections)
8	G6PD	Glucose-6-Phosphate Dehydrogenase	Protein Coding	16.65	GeneCards inferred via : Publications (show sections)
9	H6PD	Hexose-6-Phosphate Dehydrogenase/Glucose 1-Dehydrogenase	Protein Coding	16.65	GeneCards inferred via : Publications (show sections)
10	DNMT3A	DNA Methyltransferase 3 Alpha	Protein Coding	16.65	GeneCards inferred via : Publications (show sections)
11	CD22	CD22 Molecule	Protein Coding	16.65	GeneCards inferred via : Publications (show sections)
12	CTSL	Cathepsin L	Protein Coding	16.65	GeneCards inferred via : Publications (show sections)
13	SMARCA4	SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A, Member 4	Protein Coding	16.65	GeneCards inferred via : Publications (show sections)

Sources

Variations for Lymphosarcoma

Sources

Expression for Lymphosarcoma

Search GEO for disease gene expression data for Lymphosarcoma.

Sources

Pathways for Lymphosarcoma

Pathways related to Lymphosarcoma according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Chromatin Regulation / Acetylation ⁴	12.06	DNMT3A NR3C1 SMARCA4
2	B cell receptor signaling pathway (KEGG) ³⁷ Show member pathways B Cell Receptor Signaling Pathway ¹ BCR signaling pathway ¹	12.01	BCL6 CD22 PTPRC
3	DNA Damage Response ¹ Show member pathways miRNA Regulation of DNA Damage Response ¹ p53 signaling pathway ³⁷	11.98	MIR19A MIR20A MIR92A1
4	MicroRNAs in cancer ³⁷	11.93	DNMT3A MIR19A MIR20A MIR92A1
5	B Cell Receptor Signaling Pathway (sino) ⁶⁷ Show member pathways B Cell Receptor Signaling Pathway ⁶⁷	11.91	BCL6 CD22 PTPRC
6	Parkinsons Disease Pathway ¹	11.06	MIR19A MIR20A MIR92A1
7	Signaling events mediated by HDAC Class II ¹	10.9	BCL6 NR3C1
8	Hematopoietic Stem Cell Gene Regulation by GABP alpha/beta Complex ¹	10.66	DNMT3A SMARCA4
9	Sulfation Biotransformation Reaction ¹	10.54	G6PD GSR
10	B Cell Development Pathways ⁶⁵	10.52	BCL6 CD22 PTPRC

Sources

GO Terms for Lymphosarcoma

Biological processes related to Lymphosarcoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	gene silencing by miRNA	GO:0035195	9.5	MIR19A MIR20A MIR92A1
2	positive regulation of B cell proliferation	GO:0030890	9.37	BCL6 PTPRC
3	negative regulation of cardiac muscle cell apoptotic process	GO:0010667	9.26	MIR19A MIR20A
4	pentose-phosphate shunt	GO:0006098	9.16	G6PD H6PD
5	NADP metabolic process	GO:0006739	8.96	G6PD H6PD
6	negative regulation of sprouting angiogenesis	GO:1903671	8.8	MIR19A MIR20A MIR92A1

Molecular functions related to Lymphosarcoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	carbohydrate binding	GO:0030246	9.43	CD22 G6PD H6PD
2	mRNA binding involved in posttranscriptional gene silencing	GO:1903231	9.33	MIR19A MIR20A MIR92A1
3	NADP binding	GO:0050661	9.13	G6PD GSR H6PD
4	glucose-6-phosphate dehydrogenase activity	GO:0004345	8.62	G6PD H6PD

Sources

Sources for Lymphosarcoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia

Lymphosarcoma

Aliases & Classifications for Lymphosarcoma

MalaCards integrated aliases for Lymphosarcoma:

Classifications:

External Ids:

Summaries for Lymphosarcoma

Related Diseases for Lymphosarcoma

Diseases related to Lymphosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Lymphosarcoma:

Symptoms & Phenotypes for Lymphosarcoma

GenomeRNAi Phenotypes related to Lymphosarcoma according to GeneCards Suite gene sharing:

Drugs & Therapeutics for Lymphosarcoma

Drugs for Lymphosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Inferred drug relations via UMLS 73 / NDF-RT 51 :

Genetic Tests for Lymphosarcoma

Anatomical Context for Lymphosarcoma

MalaCards organs/tissues related to Lymphosarcoma:

Publications for Lymphosarcoma

Articles related to Lymphosarcoma:

Genes for Lymphosarcoma

Genes related to Lymphosarcoma (0 elite genes):

Variations for Lymphosarcoma

Expression for Lymphosarcoma

Pathways for Lymphosarcoma

Pathways related to Lymphosarcoma according to GeneCards Suite gene sharing:

GO Terms for Lymphosarcoma

Biological processes related to Lymphosarcoma according to GeneCards Suite gene sharing:

Molecular functions related to Lymphosarcoma according to GeneCards Suite gene sharing:

Sources for Lymphosarcoma

Inferred drug relations via UMLS ⁷³ / NDF-RT ⁵¹ :